Singapore markets closed

Panbela Therapeutics, Inc. (PBLA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.6700-0.0048 (-0.71%)
At close: 03:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.6748
Open0.6200
Bid0.0000 x 900
Ask0.0000 x 1200
Day's range0.5990 - 0.6900
52-week range0.4110 - 477.0000
Volume92,549
Avg. volume726,148
Market cap2.332M
Beta (5Y monthly)0.82
PE ratio (TTM)N/A
EPS (TTM)-157.0200
Earnings date02 May 2024 - 06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est410.00
  • GlobeNewswire

    Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results

    MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2023. As previously announced, management is hosting earnings call today at 4:30 p.m. ET. 2023 and early 2024 Highlights: Collaborations Divestiture of Assets within Eflornith

  • GlobeNewswire

    Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024

    MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code:

  • GlobeNewswire

    Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements

    MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that, has regained compliance with applicable listing standards of The Nasdaq Stock Market (“Nasdaq”) for bid price and publicly held shares. Nasdaq has issued notice that Panbela has regained compliance for continued listing of its common stock. On February